<DOC>
	<DOC>NCT01193478</DOC>
	<brief_summary>The primary purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and activity of escalating, multiple, oral doses of GS-5885 in subjects with chronic genotype 1 Hepatitis C Virus (HCV) infection. Each participant in the study will be sequestered in the clinic for the initial 5 days of the study.</brief_summary>
	<brief_title>A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<criteria>Chronically infected with HCV genotype 1 HCV treatmentna√Øve Not coinfected with HIV or HBV HCV RNA viral load of at least 100,000 IU/mL BMI 19 to 35 kg/m2 Subject agrees to use highly effective contraception methods if female of childbearing potential or sexually active male. History of clinicallysignificant illness or any other major medical disorder that may interfere with subject treatment, assessment or compliance with the protocol Decompensated liver disease or cirrhosis or evidence of hepatocellular carcinoma Serological evidence of coinfection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or another HCV genotype Subjects with known, current use of amphetamines and/or cocaine; subjects taking methadone or buprenorphine (opioid replacement therapy) or ongoing alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV RNA</keyword>
	<keyword>multiple ascending dose</keyword>
	<keyword>NS5A</keyword>
	<keyword>GS-5885</keyword>
	<keyword>chronic genotype 1 HCV infection</keyword>
</DOC>